\u2013 Company engages U.S. critical care professionals with data-driven early warning solution<\/b><\/p>\n
MARLBOROUGH, Mass.<\/span><\/span>, May 26, 2025<\/span><\/span> \/PRNewswire\/ — VUNO, a global medical AI company, presented its flagship solution VUNO Med\u00ae<\/sup>\u2013DeepCARS\u00ae<\/sup> at the 2025 National Teaching Institute & Critical Care Exposition (NTI), hosted by the American Association of Critical-Care Nurses (AACN), from May 19\u201321 at the Ernest N. Morial Convention Center in New Orleans<\/span>.<\/p>\n DeepCARS is an AI-powered medical device that predicts an inpatient’s risk of in-hospital cardiac arrest within the next 24 hours. By continuously analyzing patients’ vital signs\u2014such as blood pressure, heart rate, respiratory rate, and body temperature\u2014 the solution enables timely clinical intervention in general wards.<\/p>\n “Collaborating with AACN members has reaffirmed how DeepCARS can meaningfully contribute to both hospital efficiency and patient safety\u2014empowering clinicians with timely insights that lead to proactive, life-saving care,” said Robert Tingley<\/span>, Vice President of Business Development at VUNO. “We sincerely thank the critical care community for their thoughtful engagement and valuable insight.”<\/p>\n At AACN NTI 2025, VUNO’s booth drew significant attention from clinical professionals, particularly members of Rapid Response Teams (RRTs) seeking innovative tools to detect patient deterioration earlier and respond more effectively. The VUNO team\u2014including Robert Tingley<\/span>, Andrew Abbring<\/span> (Area Sales Director), and Tae Min Son<\/span> (Director of Product Management)\u2014engaged with healthcare stakeholders to better understand the needs and workflows of U.S. hospitals.<\/p>\n DeepCARS has been adopted across more than 48,000 hospital beds in South Korea<\/span>, including 20 tertiary general hospitals, making it a critical component of routine care. In 2023, the solution received Breakthrough Device Designation (BDD) from the U.S. Food and Drug Administration (FDA) and is currently undergoing the FDA 510(k) clearance process.<\/p>\n As the company strengthens its presence in the U.S. market, it continues to focus on working closely with healthcare providers to ensure successful integration into existing clinical workflows and environments.<\/p>\n About VUNO<\/b><\/p>\n Founded in Seoul<\/span> in 2014, VUNO is a global medical AI company and the developer of the nation’s first approved AI-powered medical device. Leveraging cutting-edge AI technology, VUNO analyzes a wide range of medical data\u2014from bio signals such as ECG, respiratory rate and blood pressure to medical images including X-rays, CT scans, and fundus images\u2014to predict critical events and support clinicians in decision-making. Committed to patient-centered innovation, VUNO strives to make high-quality healthcare accessible to everyone, worldwide.<\/p>","protected":false},"excerpt":{"rendered":" <\/p>\n \u2013 Company engages U.S. critical care professionals with data-driven early warning solution<\/b><\/p>\n MARLBOROUGH, Mass.<\/span><\/span>, May 26, 2025<\/span><\/span> \/PRNewswire\/ — VUNO, a global medical AI company, presented its flagship solution VUNO Med\u00ae<\/sup>\u2013DeepCARS\u00ae<\/sup> at the 2025 National Teaching Institute & Critical Care Exposition (NTI), hosted by the American Association of Critical-Care Nurses (AACN), from May 19\u201321 at the Ernest N. Morial Convention Center in New Orleans<\/span>.<\/p>\n DeepCARS is an AI-powered medical device that predicts an inpatient’s risk of in-hospital cardiac arrest within the next 24 hours. By continuously analyzing patients’ vital signs\u2014such as blood pressure, heart rate, respiratory rate, and body temperature\u2014 the solution enables timely clinical intervention in general wards.<\/p>\n “Collaborating with AACN members has reaffirmed how DeepCARS can meaningfully contribute to both hospital efficiency and patient safety\u2014empowering clinicians with timely insights that lead to proactive, life-saving care,” said Robert Tingley<\/span>, Vice President of Business Development at VUNO. “We sincerely thank the critical care community for their thoughtful engagement and valuable insight.”<\/p>\n At AACN NTI 2025, VUNO’s booth drew significant attention from clinical professionals, particularly members of Rapid Response Teams (RRTs) seeking innovative tools to detect patient deterioration earlier and respond more effectively. The VUNO team\u2014including Robert Tingley<\/span>, Andrew Abbring<\/span> (Area Sales Director), and Tae Min Son<\/span> (Director of Product Management)\u2014engaged with healthcare stakeholders to better understand the needs and workflows of U.S. hospitals.<\/p>\n DeepCARS has been adopted across more than 48,000 hospital beds in South Korea<\/span>, including 20 tertiary general hospitals, making it a critical component of routine care. In 2023, the solution received Breakthrough Device Designation (BDD) from the U.S. Food and Drug Administration (FDA) and is currently undergoing the FDA 510(k) clearance process.<\/p>\n As the company strengthens its presence in the U.S. market, it continues to focus on working closely with healthcare providers to ensure successful integration into existing clinical workflows and environments.<\/p>\n About VUNO<\/b><\/p>\n Founded in Seoul<\/span> in 2014, VUNO is a global medical AI company and the developer of the nation’s first approved AI-powered medical device. Leveraging cutting-edge AI technology, VUNO analyzes a wide range of medical data\u2014from bio signals such as ECG, respiratory rate and blood pressure to medical images including X-rays, CT scans, and fundus images\u2014to predict critical events and support clinicians in decision-making. Committed to patient-centered innovation, VUNO strives to make high-quality healthcare accessible to everyone, worldwide.<\/p>\n <\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-24406","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/24406","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24406"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/24406\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24406"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24406"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24406"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}